Lyra Therapeutics (LYRA) Accumulated Depreciation & Amortization (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $4.3 million as the latest value for Q1 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $4.3 million in Q1 2025 year-over-year; TTM through Mar 2025 was $4.3 million, a N/A change, with the full-year FY2023 number at $1.9 million, down 53.98% from a year prior.
- Accumulated Depreciation & Amortization was $4.3 million for Q1 2025 at Lyra Therapeutics, up from $4.1 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.4 million in Q2 2022 to a low of $1.9 million in Q4 2023.
- A 5-year average of $3.8 million and a median of $4.1 million in 2022 define the central range for Accumulated Depreciation & Amortization.
- Biggest YoY gain for Accumulated Depreciation & Amortization was 53.98% in 2023; the steepest drop was 53.98% in 2023.
- Lyra Therapeutics' Accumulated Depreciation & Amortization stood at $3.6 million in 2021, then rose by 15.91% to $4.2 million in 2022, then crashed by 53.98% to $1.9 million in 2023, then surged by 114.68% to $4.1 million in 2024, then rose by 3.23% to $4.3 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Accumulated Depreciation & Amortization are $4.3 million (Q1 2025), $4.1 million (Q3 2024), and $1.9 million (Q4 2023).